Research Team
Professor George Kannourakis
MB, BS, B(Med)Sc, PhD, FRACP - Honorary
Honorary Director
George oversees all research and administration at the Institute. He has a wealth of experience in cancer cell biology, having obtained his PhD from The University of Melbourne for his research at the Walter and Eliza Hall Institute of Medical Research. George is Adjunct Professor of Cancer Biology at Federation University and has been a practising oncologist and clinician haematologist in the Ballarat community for many years. George has worked at the Dana Faber Cancer Institute in Boston and as a Research Fellow at Harvard University, and he headed the Cancer Research Unit at the Royal Children’s Hospital in Melbourne.
Publications
- In Vitro and In Silico Analysis of Epithelial-Mesenchymal Transition and Cancer Stemness as Prognostic Markers of Clear Cell Renal Cell Carcinoma.
Journal: Cancers
Date: May 2023
- Knock down of TIMP-2 by siRNA and CRISPR/Cas9 mediates diverse cellular reprogramming of metastasis and chemosensitivity in ovarian cancer
Journal: Cancer Cell International
Date: Feb 2023
- Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial–mesenchymal transition interlinked with reprogrammed metabolism
Journal: Journal of Translational Medicine
Date: Dec 2022
- Crosstalk between immune checkpoint modulators, metabolic reprogramming and cellular plasticity in Triple-Negative Breast Cancer
Journal: Current Oncology
Date: Oct 2022
- Expression of TIMPs and MMPs in Ovarian Tumours, Ascites, Ascites-Derived Cells, and Cancer Cell Lines: Characteristic Modulatory Response Before and After Chemotherapy Treatment
Journal: Frontiers in Oncology
Date: Jan 2022
- Does CD1a Expression Influence T Cell Function in Patients With Langerhans Cell Histiocytosis?
Journal: Front. Immunol
Date: Dec 21
- Sphingosine 1-phosphate receptor 5 (S1PR5) regulates the peripheral retention of tissue-resident lymphocytes
Journal: J Exp Med
Date: Oct 21
- Langerhans cell histiocytosis: A malignant myeloid neoplasm or disorder of immune regulation?
Journal: Acta Paediatrica
Date: June 21
- Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma
Journal: Journal of Experimental & Clinical Cancer Research
Date: June 2021
- Prognostic Role of Immune Checkpoint Regulators in Cholangiocarcinoma: A Pilot Study
Journal: Journal of Clinical Medicine
Date: May 2021
- The attributes of plakins in cancer and disease: perspectives on ovarian cancer progression, chemoresistance and recurrence
Journal: BMC
Date: May 2021
- Determinants of Resistance to VEGF-TKI and Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma
Journal: Journal of Experimental & Clinical Cancer Research
Date: April 2021
- When Langerhans met Crohn- intestinal inflammation in disguise
Journal: Acta Paediatrica
Date: September 2020
- Aberrant Pregnancy-Associated Plasma Protein-A expression in breast cancers prognosticates clinical outcomes
Journal: Scientific Reports
Date: August 2020
- TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells
Journal: BMC Cancer
Date: Oct 2020
- A Role for MAIT Cells in Colorectal Cancer
Journal: Frontiers in Immunology
Date: May 2020
- Foxp3+ Tregs from Langerhans cell histiocytosis lesions co-express CD56 and have a definitively regulatory capacity
Journal: Clinical Immunology
Date: April 2020
- Ovarian Cancer, Cancer Stem Cells and Current Treatment Strategies: A Potential Role of Magmas in the Current Treatment Methods
Journal: Cells
Date: March 2020
- Chronically stimulated human MAIT cells are unexpectedly potent IL-13 producers
Journal: Immunology & Cell Biology 2019
Date: July 2019
- Accuracy and Prognostic Significance of Oncologists’ Estimates and Scenarios for Survival Time in Advanced Gastric Cancer
Journal: The Oncologist
Date: April 2019
- Paclitaxel-Induced Src Activation Is Inhibited by Dasatinib Treatment, Independently of Cancer Stem Cell Properties, in a Mouse Model of Ovarian Cancer
Journal: Cancers
Date: Feb 19
- Altered Populations of Unconventional T Cell Lineages in Patients with Langerhans Cell Histiocytosis
Journal: Scientific Reports
Date: Dec 2018
- Tumour Microenvironment and Metabolic Plasticity in Cancer and Cancer Stem Cells: Perspectives on Metabolic and Immune Regulatory Signatures in Chemoresistant Ovarian Cancer Stem Cells.
Journal: Seminars in Cancer Biology
Date: Jul 18
- A potentially important role for T cells and regulatory T cells in Langerhans cell histiocytosis
Journal: Clinical Immunology
Date: June 2018
- The Many Facets of Metzincins and Their Endogenous Inhibitors: Perspectives on Ovarian Cancer Progression.
Journal: International Journal Molcular Science
Date: Jan 2018
- Momelotinib decreased cancer stem cell associated tumor burden and prolonged disease-free remission period in a mouse model of human ovarian cancer.
Journal: Oncotarget
Date: Mar 2018
- Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma.
Journal: Gastric Cancer
Date: Aug 2017
- Knockdown of stem cell regulator Oct4A in ovarian cancer reveals cellular reprogramming associated with key regulators of cytoskeleton-extracellular matrix remodelling.
Journal: Scientific Reports
Date: April 2017
- Knockdown of stem cell regulator Oct4A in ovarian cancer reveals cellular reprogramming associated with key regulators of cytoskeleton-extracellular matrix remodeling.
Journal: Scientific Reports
Date: April 2017
- Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma and positive interim PET after 4 cycles of R-CHOP-14.
Journal: Haematologica
Date: Nov 2016
- Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer Cancer
Journal: N Engl J Med
Date: Oct 2016
- Unique proteome signature of post-chemotherapy ovarian cancer ascites-derived tumor cells.
Journal: Sci Rep
Date: July 2016
- Coalition of Oct4A and β1 integrins in facilitating metastasis in ovarian cancer
Journal: BMC Cancer
Date: July 2016
- Evaluation of response from axitinib per Response Evaluation Criteria in Solid Tumors versus Choi criteria in previously treated patients with metastatic renal cell carcinoma.
Journal: Onco Targets Ther
Date: May 2016
- Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial.
Journal: Ann Oncol
Date: Feb 2016
- Resolution of norfloxacin-induced acute liver failure after N-acetylcysteine therapy: further support for the use of NAC in drug-induced ALF?
Journal: BMJ Case Rep
Date: Jan 2016
- Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Journal: Lancet
Date: 2016
- Use of Suppression Subtractive Hybridization for Viral Diagnostics
Journal: British Journal of Virology
Date: 2016
- Suppression subtractive hybridization method for the identification of a new strain of murine hepatitis virus from xenografted SCID mice.
Journal: Arch Virol
Date: Sept 2015
- An emerging role for immune regulatory subsets in chronic lymphocytic leukaemia.
Journal: Int Immunopharmacol
Date: April 2015
- EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma.
Journal: Ann Oncol
Date: Feb 2015
- Adjuvant ovarian suppression in premenopausal breast cancer.
Journal: The New England Journal of Medicine
Date: Jan 2015
- Polyclonal T-cells express CD1a in Langerhans cell histiocytosis (LCH) lesions.
Journal: PLoS One
Date: Oct 2014
- Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
Journal: The New England Journal of Medicine
Date: July 2014
- Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial.
Journal: Br J Cancer
Date: May 2014
- Acute exercise leads to regulation of telomere-associated genes and microRNA expression in immune cells.
Journal: PLoS One
Date: April 2014
- Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem)
Journal: Breast
Date: April 2014
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Journal: Lancet
Date: May 2013
- Breast-cancer adjuvant therapy with zoledronic acid.
Journal: The New England Journal of Medicine
Date: Oct 2011
- Adjuvant trastuzumab in HER2-positive breast cancer.
Journal: The New England Journal of Medicine
Date: Oct 2011
- A cryptic deletion in 5q31.2 provides further evidence for a minimally deleted region in myelodysplastic syndromes.
Journal: Cancer Genet
Date: Apr 2011
- The Severe Chronic Neutropenia International Registry: 10-Year Follow-up Report.
Journal: American Journal of Hematology
Date: Jun 2005
- Neutrophil elastase mutations and risk of leukaemia in severe congenital neutropenia.
Journal: Br J Haematol
Date: Nov 2007
- Three cases of activation of cutaneous squamous-cell carcinoma during treatment with prolonged administration of rituximab.
Journal: Clin Oncol
Date: Jun 2005
- The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy.
Journal: Blood
Date: Feb 2006
- Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry.
Journal: American Journal of Hematology
Date: 2003
- A time to kill: viral manipulation of the cell death program.
Journal: Journal of General Virology
Date: July 2002
- Glycogen storage disease.
Journal: Semin Hematol
Date: Apr 2002
- Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia.
Journal: Blood
Date: Oct 2000
- Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy.
Journal: Blood
Date: July 2000
- Novel endogenous type D retroviral particles expressed at high levels in a SCID mouse thymic lymphoma.
Journal: Journal of Virology
Date: Jun 1999
- Perivascular T cells express the pro-inflammatory chemokine RANTES mRNA in multiple sclerosis lesions.
Journal: Scand J Immunol
Date: Mar 1997
- Leukemia inhibitory factor and interleukin-6 are produced by diseased and regenerating skeletal muscle.
Journal: Muscle Nerve
Date: Oct 1996
- EWS/FLI-1 fusion transcript detection and MIC2 immunohistochemical staining in the diagnosis of Ewing's sarcoma.
Journal: Pediatr Pathol Lab Med
Date: May 1996
- Cytogenetic and DNA analysis of two neuroectodermal tumors without a simple t(11;22).
Journal: Cancer Genet Cytogenet
Date: Aug 1995
- Soluble antigen can cause enhanced apoptosis of germinal-centre B cells.
Journal: Nature
Date: May 1995
- bcl-2 transgene expression can protect neurons against developmental and induced cell death.
Journal: Proc Natl Acad Sci U S A
Date: May 1995
- Viable bone marrow stromal cells are required for the in vitro survival of B-cell precursor acute lymphoblastic leukemic cells.
Journal: Leukemia Research
Date: Feb 1995
- Flow cytometric analysis of intercellular adhesion between B-cell precursor acute lymphoblastic leukemic cells and bone marrow stromal cells.
Journal: Leukemia
Date: Jan 1995
- Kiz-1, a protein with LIM zinc finger and kinase domains, is expressed mainly in neurons
Journal: Cell Growth Differentiation
Date: Nov 1994
- The role of cytokines in the pathogenesis of Langerhans cell histiocytosis.
Journal: Br J Cancer Suppl
Date: Sept 1994
- The biology of erythropoietin and its role in the anaemia of prematurity
Journal: Journal of Paediatric Child Health
Date: Aug 1994
- Human bone marrow stromal cell contact and soluble factors have different effects on the survival and proliferation of paediatric B-lineage acute lymphoblastic leukaemic blasts.
Journal: Leuk Res
Date: May 1994
- Dose-intensive cyclophosphamide with etoposide and vincristine for paediatric solid tumors: a phase I/II pilot study by the Australia and New Zealand Childhood Cancer Study Group.
Journal: Journal of Clinical Oncology
Date: Mar 1994
- Measurement of the growth parameters of precursor B-acute lymphoblastic leukaemic cells in co-culture with bone marrow stromal cells; detection of two cd10 positive populations with different proliferative capacities and survival.
Journal: Leuk Res
Date: Jan 1994
- A novel approach to the measurement of different in vitro leukaemic cell growth parameters: the use of PKH GL fluorescent probes.
Journal: Leuk Res
Date: Oct 1993
- Characterization of stroma-adherent colony-forming cells: a clonogenic assay for early hemopoietic cells?
Journal: Exp Hematol
Date: mar 1993
- SCL gene in human tumors.
Journal: Leukemia
Date: Jul 1992
- Proliferative properties of unfractionated, purified, and single cell human progenitor populations stimulated by recombinant human interleukin-3
Journal: Blood
Date: Jan 1990
- Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients.
Journal: Blood
Date: Dec 1988
- Enhancement of in vitro beta-thalassemic and normal hematopoiesis by a noncytotoxic monoclonal antibody, 9.1C3: evidence for negative regulation of hematopoiesis by monocytes and natural killer cells.
Journal: Blood
Date: Oct 1988
- Pharmacokinetics of human granulocyte-macrophage colony-stimulating factor using a sensitive immunoassay
Journal: Blood
Date: Nov 1988
- Clinical studies with granulocyte colony stimulating factor (G-CSF) in patients receiving cytotoxic chemotherapy.
Journal: Behring Inst Mitt
Date: Aug 1988
- Activated killer cell lymphoma: an erythrophagocytic syndrome simulating histiocytic medullary histiocytosis.
Journal: Pathology
Date: July 1988
- Clonal proliferation in vitro of individual murine and human hemopoietic cells after fluorescence-activated cell sorting.
Journal: Exp Hematol
Date: Jun 1988
- Evidence for interactions between monocytes and natural killer cells in the regulation of in vitro hemopoiesis
Journal: Journal of Immunology
Date: Apr 1988
- Fractionation of subsets of BFU-E from normal human bone marrow: responsiveness to erythropoietin, human placental-conditioned medium, or granulocyte-macrophage colony-stimulating factor.
Journal: Blood
Date: Mar 1988
- A human complement-fixing monoclonal anti-human lymphocyte antibody of rat origin.
Journal: Immunology and Cell Biology
Date: Jun 2005
- Fractionation of normal and beta-thalassemic human hemopoietic progenitor cells by immunomagnetic beads.
Journal: Exp Hematol
Date: Dec 1987
- Transgenic mice expressing a hemopoietic growth factor gene (GM-CSF) develop accumulations of macrophages, blindness, and a fatal syndrome of tissue damage.
Journal: Cell
Date: Nov 1987
- Studies by radioiodination of normal adult, fetal and leukemic cell membranes.
Journal: Exp Hematol
Date: Sept 1987
- Osmotic fragility of leukaemic and normal lymphocytes
Journal: Pathology
Date: Apr 1987
Professor Nuzhat Ahmed
BSc Hons (DU), MSc (KUL), PhD (ANU
John Turner Professorial Fellow
Nuzhat joined the Institute in 2015 and is the John Turner Professorial Fellow. She holds an adjunct professorial position with the Federation University, Ballarat which strengthens links between the Institute and the University. Professor Ahmed is an experienced cell and molecular biologist and brings a wealth of experience to Institute, particularly in cancer biology. She has a long-standing interest in understanding the molecular mechanisms of ovarian cancer spread. She did her postdoctoral research training in Malaghan Institute of Medical Research, New Zealand, University of Newcastle, Australia, Kanagawa Cancer Centre, Japan and BC Cancer Agency, University of British Columbia in Canada. From 2002-2014 Nuzhat led the Cancer Metastasis Group in Women’s Cancer Research Centre, Royal Women’s Hospital, Melbourne. Her significant contribution has been in establishing novel interactions of cell adhesion molecules with the signalling pathways in cancer, identifying early stage biomarkers for ovarian cancer screening and understanding the mechanisms of chemoresistance in ovarian cancer patients. These studies have led to several international patents, competitive international and national grants and publications (>80) in reputable cancer journals. Nuzhat has a long-standing interest in understanding the immune cell irregularities in ovarian cancer patients.
Publications
- In Vitro and In Silico Analysis of Epithelial-Mesenchymal Transition and Cancer Stemness as Prognostic Markers of Clear Cell Renal Cell Carcinoma.
Journal: Cancers
Date: May 2023
- Knock down of TIMP-2 by siRNA and CRISPR/Cas9 mediates diverse cellular reprogramming of metastasis and chemosensitivity in ovarian cancer
Journal: Cancer Cell International
Date: Feb 2023
- Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial–mesenchymal transition interlinked with reprogrammed metabolism
Journal: Journal of Translational Medicine
Date: Dec 2022
- Expression of TIMPs and MMPs in Ovarian Tumours, Ascites, Ascites-Derived Cells, and Cancer Cell Lines: Characteristic Modulatory Response Before and After Chemotherapy Treatment
Journal: Frontiers in Oncology
Date: Jan 2022
- Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma
Journal: Journal of Experimental & Clinical Cancer Research
Date: June 21
- The attributes of plakins in cancer and disease: perspectives on ovarian cancer progression, chemoresistance and recurrence
Journal: BMC
Date: May 2021
- Determinants of Resistance to VEGF-TKI and Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma
Journal: Journal of Experimental & Clinical Cancer Research
Date: April 2021
- TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells
Journal: BMC Cancer
Date: Oct 2020
- In Vitro and In Vivo Toxicity and Biodistribution of Paclitaxel-Loaded Cubosomes as a Drug Delivery Nanocarrier: A Case Study Using an A431 Skin Cancer Xenograft Model
Journal: Applied Bio Materials
Date: June 2020
- Ovarian Cancer, Cancer Stem Cells and Current Treatment Strategies: A Potential Role of Magmas in the Current Treatment Methods
Journal: Cells
Date: March 2020
- The Potential Role of Interleukin-11 in Epithelial Ovarian Cancer
Journal: Journal of Cancer Science and Clinical Therapeutics
Date: Feb 2019
- Paclitaxel-Induced Src Activation Is Inhibited by Dasatinib Treatment, Independently of Cancer Stem Cell Properties, in a Mouse Model of Ovarian Cancer.
Journal: Cancers
Date: Feb 2019
- Tumour Microenvironment and Metabolic Plasticity in Cancer and Cancer Stem Cells: Perspectives on Metabolic and Immune Regulatory Signatures in Chemoresistant Ovarian Cancer Stem Cells.
Journal: Seminars in Cancer Biology
Date: Jul 2018
- Paclitaxel-loaded self-assembled lipid nanoparticles as targeted drug delivery systems for the treatment of aggressive ovarian cancer
Journal: ACS Applied Materials & Interfaces
Date: Jul 2018
- Momelotinib decreased cancer stem cell associated tumor burden and prolonged disease-free remission period in a mouse model of human ovarian cancer.
Journal: Oncotarget
Date: March 2018, Vol. 9, (No. 24), pp: 16599-16618
- The Many Facets of Metzincins and Their Endogenous Inhibitors: Perspectives on Ovarian Cancer Progression.
Journal: International Journal of Molecular Sciences Review
Date: Jan 2018
- Surface Profiling of Extracellular Vesicles from Plasma or Ascites Fluid Using DotScan Antibody Microarrays- Chapter 20.
Journal: Methods Molecular Biology, Vol. 1619, Serum/Plasma Proteomics, 978-1-4939-7056-8
Date: 2017
- Knockdown of stem cell regulator Oct4A in ovarian cancer reveals cellular reprogramming associated with key regulators of cytoskeleton-extracellular matrix remodeling.
Journal: Scientific Reports
Date: April 2017
- Coalition of Oct4A and β1 integrins in facilitating metastasis in ovarian cancer.
Journal: Scientific Reports
Date: Jul 2016
- Molecular pathways regulating epidermal growth factor-induced epithelio-mesenchymal transition in human ovarian surface epithelium.
Journal: American Journal of Physiology: Cell Physiology
Date: July 2016
- Unique proteome signature of post-chemotherapy ovarian cancer ascites-derived tumor cells
Journal: Scientific Reports
Date: July 2016
- Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead.
Journal: Carcinogenesis
Date: Jun 2015
- Tumour Microenvironment and Metabolic Plasticity in Cancer and Cancer Stem Cells: Perspectives on Metabolic and Immune Regulatory Signatures in Chemoresistant Ovarian Cancer Stem Cells.
Journal: Seminars in Cancer Biology
Date: Jul 2018
- A critical role of Oct4A in mediating metastasis and disease-free survival in a mouse model of ovarian cancer.
Journal: Molecular Cancer
Date: Aug 2015
- Enhanced activation of STAT3 in ascites-derived recurrent ovarian tumors: inhibition of cisplatin-induced STAT3 activation reduced tumorigenicity of ovarian cancer by a loss of cancer stem cell-like characteristics.
Journal: Journal of Cancer Stem Cell Research
Date: January 2015
- Distinct molecular signature of recurrent ovarian tumor cells isolated from the ascites of advanced-stage serous ovarian cancer patients.
Journal: Journal of Cancer Stem Cell Research
Date: October 2014
- Betaglycan blocks metastatic behaviors in human granulosa cell tumors by suppressing NFkB-mediated induction of MMP2.
Journal: Cancer Letters
Date: Nov 2014
- Targeted disruption of JAK2/STAT3 pathway in combination with systemic administration of paclitaxel inhibits the priming of ovarian cancer stem cells leading to a reduced tumor burden.
Journal: Frontiers in Oncology
Date: May 2014
- Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden
Journal: BMC Cancer
Date: May 2014
- Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer
Journal: Br J Cancer
Date: Nov 2013
- Ovarian cancer stem cells: Molecular concepts and relevance as therapeutic targets.
Journal: Molecular Aspects of Medicine
Date: Jun 2013
- Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden.
Journal: Molecular Cancer
Date: Mar 2013
- Getting to know ovarian cancer ascites: Opportunities for targeted therapy-based translational research
Journal: Frontiers in Oncology
Date: Sep 2013
- Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance
Journal: Journal of Cellular Biochemistry
Date: Jan 2013
- Investigation of human cationic antimicrobial protein-18 (hCAP-18), lactoferrin and CD163 as potential biomarkers for ovarian cancer
Journal: Journal of Ovarian Research
Date: Jan 2013
- Attributes of Oct4 in stem cell biology: Perspectives on cancer stem cells of the ovary
Journal: Journal of Ovarian Research
Date: Nov 2012
- Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemo resistant ovarian tumors
Journal: PloS One
Date: Oct 2012
- Contribution of fibroblast and mast cell (afferent) and tumor (efferent) IL-6 effects within the tumor micro-environment
Journal: Cancer Microenvironment
Date: Apr 2012
- Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profiles
Journal: Journal of Cellular Biochemistry
Date: Oct 2011
- 2D-PAGE of Ovarian Cancer: Analysis of soluble and insoluble fractions using narrow pH ranges
Journal: Biochemical and Biophysical Research Communication
Date: Feb 2011
- Effect of silencing neutrophil gelatinase-associated lipocalin in ovarian cancer cells on epithelio-mesenchymal transition.
Journal: Journal of Molecular Biomarkers and Diagnosis
Date: Aug 2011
- Multicellular spheroids in ovarian cancer metastases: Biology and pathology.
Journal: Gynecology Oncology
Date: Apr 2009
- Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemo resistance in recurrent ovarian cancer
Journal: Current Cancer Drug Target
Date: Apr 2010
- Neuronal transcription factor Brn-3a is over expressed in high-grade ovarian carcinomas and tumor cells from ascites of patients with advanced-stage ovarian cancer.
Journal: Journal of Ovarian Research
Date: Jul 2010
- Epidermal growth factor induced ovarian carcinoma cell migration is associated with JAK2/STAT3 signals and changes in the abundance and localization of a6b1 integrin.
Journal: International Journal of Biochemistry Cell Biology
Date: Dec 2008
- Cross talk of signals between EGFR and IL-6R via JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas.
Journal: British Journal of Cancer
Date: Dec 2008
- Epithelial-Mesenchymal interconversions in normal ovarian epithelium and ovarian carcinomas: an exception to the norm
Journal: Journal of Cellular Physiology
Date: Dec 2007
- Immunohistochemical perspective of PPARb and one of its putative targets PDK1 in normal ovaries, benign and malignant ovarian tumours
Journal: British Journal of Cancer
Date: May 2008
- Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epithelio-mesenchymal transition.
Journal: International Journal of Cancer
Date: Feb 2007
- a2b1 integrin affects metastatic ability of ovarian carcinoma spheroids by supporting disaggregation and proteolysis.
Journal: Journal of Carcinogenesis
Date: Jun 2007
- Molecular pathways regulating epidermal growth factor-induced epithelio-mesenchymal transition in human ovarian surface epithelium
Journal: American J of Physiology: Cell Physiology
Date: 2007
- Proteomics tracking of serum protein isoforms as screening biomarkers of ovarian cancer.
Journal: Proteomics
Date: Nov 2005
- Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix micro-environment.
Journal: Clin Expt Metastasis
Date: Jun 2005
- Ascites induces modulation of a6 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma.
Journal: British Journal of Cancer
Date: Apr 2005
- Translational Proteomics: Developing a predictive capacity.
Journal: Placenta
Date: Nov 2005
- Strategies for revealing lower abundance proteins in two-dimensional protein maps.
Journal: Journal of Chromatography
Date: Mar 2005
- Enhanced expression of peroxisome proliferator receptor g expression in ovarian carcinoma.
Journal: British Journal of Cancer
Date: Jan 2005
- Proteomics based identification of hatoglobin-1 precursor as a novel circulating biomarker for ovarian cancer.
Journal: British Journal of Cancer
Date: Jun 2004
- Cell-free 59 kDa Immunoreactive integrin-linked kinase: a novel marker for ovarian carcinoma.
Journal: Clinical Cancer Research
Date: Apr 2004
- Expression and localization of avb6 integrin in extraplacental fetal membranes: possible role in human parturition.
Journal: Molecular Human Reproduction
Date: Jan 2004
- Integrin-linked kinase expression increases with ovarian tumour grade and is sustained by peritoneal tumour fluid.
Journal: Journal of Pathology
Date: Oct 2003
- Down regulation of urokinase plasminogen activator expression inhibits Erk signaling with concomitant suppression of matrix metalloprotease-9 (MMP-9) due to loss of uPAR-b1 integrin complex in colon cancer.
Journal: British Journal of Cancer
Date: Jul 2003
- Proteomic profiling of proteins associated with urokinase plasminogen activator receptor (uPAR) in colon cancer cells using an antisense approach
Journal: Proteomics
Date: Mar 2003
- avb6 Integrin- A marker for the malignant potential of epithelial ovarian cancer
Journal: J Hist. Cytochem
Date: Oct 2002
- Integrin expression in colon cancer cells is regulated by the cytoplasmic domain of the b6 integrin subunit.
Journal: International Journal of Cancer
Date: Apr 2002
- Direct integrin avb6-Erk binding: implications for tumour growth
Journal: Oncogene
Date: Feb 2002
- Overexpression of avb6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade.
Journal: Carcinogenesis
Date: Feb 2002
- The avb6 integrin regulates its own expression with cell crowding: implications for tumor progression.
Journal: nt. J. Cancer
Date: Apr 2001
- Ceramides that mediate apoptosis reduce glucose uptake and transporter affinity for glucose in human leukaemic cell lines but not in neutrophils
Journal: Pharmacology and Toxicology
Date: Sep 1999
- Distinct regulation of glucose transport by Interleukin-3 and oncogenes in a murine bone marrow derived cell line
Journal: Biochemical Pharmacology
Date: Sep 1999
- N -glycosylation of glucose transporter-1 (Glut-1) is associated with increased transporter affinity for glucose in human leukemic cells
Journal: Leukemia Research
Date: Apr 1999
- New insights into mammalian sugar transport and its regulation at the plasma membrane
Journal: NZ BioScience
Date: 1999
- IL-3 induces apoptosis: Differential effect of IL-3 on the survival and growth response of parental and oncogene-transfected cells
Journal: Apoptosis
Date: 1999
- Transforming oncogenes regulate glucose transport by increasing transporter affinity for glucose: Contrasting effects of oncogenes and heat stress in a murine bone marrow-derived cell line.
Journal: Life Sciences
Date: 1998
- Telomerase activity in a specific cell subset coexpressing integrin b1/EGFR but not p75NGFR/bcl2 in normal human epithelial cell.
Journal: Oncogene
Date: Aug 1998
- Acute regulation of glucose transport after activation of human peripheral blood neutrophils by phorbol myristate acetate, fMLP and granulocyte-macrophage colony-stimulating factor.
Journal: Blood
Date: 1998
- Acute regulation of glucose transport in a monocyte-macrophage cell line: Glut-3 activity for glucose is enhanced during the respiratory burst.
Journal: Biochem J
Date: Oct 1997
- Regulation of glucose transport by interleukin-3 in growth factor-dependent and oncogene-transformed bone marrow derived cell lines.
Journal: Leukemia Research
Date: Jul 1997
- The hemopoietic growth factor, interleukin-3, promotes glucose transport by increasing the specific activity and maintaining the affinity for glucose of plasma membrane glucose transporters in a bone marrow-derived cell line: Possible involvement of phosphorylation in the activation of transporters.
Journal: J Biol. Chem.
Date: Jul 1997
- Interaction of reactive nitrogen and oxygen intermediates in HL60 and dimethyl sulphoxide-differentiated HL60 cells
Journal: Leukemia Research
Date: Mar 1997
- Biochemical effect of three different inhibitors of purine/pyrimidine metabolism on differentiation in HL60 cells.
Journal: Leukemia Research
Date: Apr 1995
- Purine metabolism in promyelocytic HL60 and dimethyl sulphoxide-differentiated HL60 cells.
Journal: Leukemia Research
Date: Jun 1994
- Glycolytic, glutaminolytic and pentose-phosphate pathways in promyelocytic HL60 and DMSO-differentiated HL60 cells.
Journal: Biochem. & Mol. Biol. Int
Date: Apr 1993
- The Human promyelocytic HL60 cell line: A model of myeloid cell differentiation using dimethylsulphoxide, phorbol ester and butyrate.
Journal: Biochem. Int
Date: Feb 1991
- Oral Cholera vaccines containing b-subunit-killed whole cells and whole cells only. Cross reacting antigens of the members of family Vibrionaceae and the vaccines.
Journal: Vaccine
Date: Apr 1989
- The impact of low dose carcinogens and environmental disrupters on tissue invasion and metastasis.
Journal: Carcinogenesis
Date: Feb 1991
Dr Aparna Jayachandran
BSc, MSc, PhD
Senior Research Fellow
Dr Jayachandran is an internationally recognised cancer researcher, with her most recent appointment prior the Institute was as the Head of the Liver Cancer Unit at the Gallipoli Medical Research Institute at the University of Queensland. She has also held appointments at the Liebig University, Germany and Mount Sinai School of Medicine, New York, University of Melbourne, Latrobe University, and the Olivia Newton John Cancer Research Institute. Her background and expertise in cancer biology, epithelial-to-mesenchymal transition, cancer stem cells, and organ fibrosis is an asset to the team.
Publications
- Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer
Journal: Current Oncology
Date: Oct 2022
- CD73 and PD-L1 as Potential Therapeutic Targets in Gallbladder Cancer
Journal: International Journal of Molecular Sciences
Date: Jan 2022
- Combined Inhibition of TGF-β1-Induced EMT and PD-L1 Silencing Re-Sensitizes Hepatocellular Carcinoma to Sorafenib Treatment
Journal: Journal of Clinical Medicine
Date: April 2021
- Prognostic Role of Immune Checkpoint Regulators in Cholangiocarcinoma: A Pilot Study
Journal: Journal of Clinical Medicine
Date: May 2021
- Combined inhibition of TGF-β1-induced EMT and PD-L1 silencing re-sensitizes hepatocellular carcinoma to Sorafenib treatment.
Journal: Journal of Clinical Medicine
Date: May 2020
- Immune checkpoint molecules are regulated by transforming growth factor (TGF)-β1-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma.
Journal: International Journal of Medical Sciences
Date: March 2021
- Aberrant Pregnancy-Associated Plasma Protein-A expression in breast cancers prognosticates clinical outcomes
Journal: Scientific Reports
Date: August 2020
- TNF‑α‑mediated epithelial‑to‑mesenchymal transition regulates expression of immune checkpoint molecules in hepatocellular carcinoma.
Journal: Molecular Medicine Reports
Date: April 20
- Spotlight on Bortezomib: potential in the treatment of hepatocellular carcinoma.
Journal: Expert Opin Investig Drugs.
Date: Jan 2019
- Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma.
Journal: Frontier Oncology
Date: July 2018
- Evaluation of the Glypican 3 promoter for transcriptional targeting of hepatocellular carcinoma.
Journal: Gene Ther
Date: April 2018
- Seek and destroy: targeted adeno-associated viruses for gene delivery to hepatocellular carcinoma.
Journal: Drug Delivery
Date: Nov 2017
- Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer.
Journal: Oncotarget
Date: May 2017
- Murine hepatocellular carcinoma derived stem cells reveal epithelial-to-mesenchymal plasticity.
Journal: World Journal of Stem Cells
Date: Sept 2017
- Epithelial-to-Mesenchymal Transition: A Mediator of Sorafenib Resistance in Advanced Hepatocellular Carcinoma.
Journal: Current Cancer Drug targets
Date: 2017
- Two-photon dual imaging platform for in vivo monitoring cellular oxidative stress in liver injury.
Journal: Sciencfic Reports
Date: March 2017
- Epithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in hepatocellular carcinoma.
Journal: Journal Hematology Oncology
Date: Aug 2016
- Identifying and targeting determinants of melanoma cellular invasion.
Journal: Oncotarget
Date: July 2016
- Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells.
Journal: Molecular Cancer Therapeutics
Date: June 2016
- Transketolase-like 1 ectopic expression is associated with DNA hypomethylation and induces the Warburg effect in melanoma cells.
Journal: BMC Cancer
Date: Feb 2016
- Pregnancy associated plasma protein-A links pregnancy and melanoma progression by promoting cellular migration and invasion.
Journal: Oncotarget
Date: Jun 2015
- Embryonic Chicken Transplantation is a Promising Model for Studying the Invasive Behavior of Melanoma Cells.
Journal:
Date: Feb 2015
- Effects of epithelial to mesenchymal transition on T cell targeting of melanoma cells.
Journal: Frontiers in Oncology
Date: Dec 2014
- Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanoma.
Journal: Oncotarget
Date: Jul 2014
- FOXP3 over-expression inhibits melanoma tumorigenesis via effects on proliferation and apoptosis.
Journal: Oncotarget
Date: Jan 2014
- Transgelin is a direct target of TGF-beta/Smad3-dependent epithelial cell migration in lung fibrosis.
Journal: FASAB Journal
Date: Jun 2008
- Leukocytes induce epithelial to mesenchymal transition after unilateral ureteral obstruction in neonatal mice.
Journal: American Journal of Pathology
Date: Sept 2007
Dr Monirul Islam
BSc (Hons), MSc (PhD)
Senior Scientist (Molecular Biology)
Dr. Monirul Islam joined the Institute in July 2003. Monirul obtained his Bachelor (Hons) and Master degrees in Biochemistry from the University of Dhaka, Bangladesh and his PhD in Molecular Biology from the medical faculty of Nagoya University in Japan. Before joining the Institute, Monirul was working as research associate at the Southern Methodist University, Texas, USA. Monirul also worked as a scientific officer at the Centre for Molecular Biology and Medicine, Melbourne, Australia and as a Science and Technology Agency (STA) fellow at the National Food Research Institute, Tsukuba, Japan.
Publications
- Use of Suppression Subtractive Hybridization for Viral Diagnostics
Journal: Arch Virol
Date: 2015
Dr Sharon Olsen
BSc (Hons) PhD
JG King Research Fellow
Sharon joined the Institute in May 2003. She has worked in the field of cancer research for her entire career. Sharon graduated with a Bachelor of Science degree (Honours) and a PhD from the University of Melbourne. While at St. Vincent's Institute of Medical Research, Melbourne, her PhD studied parathyroid hormone-related protein and the biology of cancer. She then traveled to Canada to work on chemotherapy resistance by multi drug resistance protein at the Cancer Research Laboratories, Queen’s University, Kingston, Ontario, prior to her return to Australia.
Dr Jenée Mitchell
BAppSc (Hons), PhD
Postdoctoral Research Fellow
Following graduation from Federation University with a Bachelor of Applied Science (Hons), Jenée joined the laboratory in 2012 as part of the team working on histiocytic diseases and completing her PhD this on the role of T cells in the immune regulation of Langerhans cell histiocytosis in 2019. She was appointed Post Doctorate Researcher at the Institute in 2020 and continues her work into Langerhans cell histiocytosis.
Publications
- Does CD1a Expression Influence T Cell Function in Patients With Langerhans Cell Histiocytosis?
Journal: Front. Immunol
Date: Dec 22
- Langerhans cell histiocytosis: A malignant myeloid neoplasm or disorder of immune regulation?
Journal: Acta Paediatrica
Date: June 2021
- When Langerhans met Crohn- intestinal inflammation in disguise
Journal: Acta Paediatrica
Date: September 2020
- Foxp3+ Tregs from Langerhans cell histiocytosis lesions co-express CD56 and have a definitively regulatory capacity
Journal: Clinical Immunology
Date: April 2020
- Altered Populations of Unconventional T Cell Lineages in Patients with Langerhans Cell Histiocytosis
Journal: Scientific Reports
Date: Dec 2019
- Co-Expression of CD56 and Production of Transforming Growth Factor Beta By Foxp3 Regulatory T Cells from Langerhans Cell Histiocytosis Lesions
Journal: Blood
Date: Dec 2018
- A potentially important role for T cells and regulatory T cells in Langerhans cell histiocytosis
Journal: Clinical Immunology
Date: June 2018
- THE ROLE OF T CELLS IN THE IMMUNE REGULATION OF LANGERHANS CELL HISTIOCYTOSIS (LCH)
Journal: Pediatric Blood & Cancer
Date: Nov 2015
- Consumption of a low glycaemic index diet in late life extends lifespan of Balb/c mice with differential effects on DNA damage
Journal: Longevity & Healthspan
Date: March 2013
Dr Rodney Luwor
BSc PhD
Post Doctoral Researcher
Dr Luwor joined the Institute in 2021, bringing with him almost two decades experience in using human cancer models and human patient samples to investigate the genetic and molecular alterations associated with cancer. Further to this Dr Luwor has expertise in developing molecular therapeutics for inhibition of tumour growth and progression. In particular, Dr Luwor has performed pre-clinical, therapeutic evaluation of several agents designed to block tumour growth. More recently, Dr Luwor has expanded his research interests to explore tumour resistance to both molecular targeted therapy and standard chemotherapy.
Dr Prashanth Prithviraj
MBBS MSc MPH FRACP PhD
Honorary Senior Research Fellow
Dr Prashanth Prithviraj, who recently completed PhD in cancer biology at The Austin Hospital (Oliva Newton-John Cancer Research Institute) joined the institute in September 2017 as Senior Research Fellow. After earning his medical degree, Prashanth pursued Medical Oncology training at Calvary Mater Newcastle Hospital, he furthered his education and completed training with a Fellowship in Medical Oncology at The Austin Hospital in Melbourne. Prashanth has extensive research experience and his other qualifications apart from FRACP include Masters of Science (Biotechnology) from University of Western Sydney and Master of Public Health (Epidemiology and Statistics) from the University of Newcastle. Prashanth has presented at major national and international meetings, and authored publications in prominent cancer related peer reviewed journals. He has a special interest in transitional research and immunotherapy, and is a lead investigator in a number of clinical trials, and also is involved in development and conduct of clinical trials. His research goals are to develop innovative models to establish EMT mechanism as an important biomarker for cancer progression, resistance to therapy and as a biomarker of responsiveness to immune therapy, with the aim of developing/designing EMT-based therapies in cancer.
Publications
- In Vitro and In Silico Analysis of Epithelial-Mesenchymal Transition and Cancer Stemness as Prognostic Markers of Clear Cell Renal Cell Carcinoma
Journal: Cancers
Date: may 2023
- Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer
Journal: Current Oncology
Date: Oct 2022
- CD73 and PD-L1 as Potential Therapeutic Targets in Gallbladder Cancer
Journal: International Journal of Molecular Sciences
Date: Jan 2022
- Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma
Journal: Journal of Experimental & Clinical Cancer Research
Date: June 2021
- Combined Inhibition of TGF-β1-Induced EMT and PD-L1 Silencing Re-Sensitizes Hepatocellular Carcinoma to Sorafenib Treatment
Journal: Journal of Clinical Medicine
Date: April 2021
- Prognostic Role of Immune Checkpoint Regulators in Cholangiocarcinoma: A Pilot Study
Journal: Journal of Clinical Medicine
Date: May 2021
- Determinants of Resistance to VEGF-TKI and Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma
Journal: Journal of Experimental & Clinical Cancer Research
Date: April 2021
- Aberrant pregnancy-associated plasma protein-A expression in breast cancers prognosticates clinical outcomes
Journal: Scientific Reports
Date: August 2020
- Reply to ‘Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy’’
Journal: British Journal of Cancer
Date: Jan 2017
- Efficacy and toxicity of treatment with the anti-CTLA-4 antibody Ipilimumab in patients with metastatic melanoma who have progressed on anti-PD-1 therapy.
Journal: Journal of Clinical Oncology
Date: Jan 2017
- abs# 11 Patterns of Use of Adjuvant Therapy in Patients with Stage 1 Nsgct
Journal: Asia-pacific Journal of Clinical Oncology
Date: Dec 2016
- Identifying and targeting determinants of melanoma cellular invasion
Journal: Oncotarget
Date: July 2016
- Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.
Journal: British Journal of Cancer
Date: May 2016
- Transketolase-like 1 ectopic expression is associated with DNA hypomethylation and induces the Warburg effect in melanoma cells
Journal: BMC cancer
Date: Feb 2016
- Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy
Journal: Journal for Immunotherapy of Cancer
Date: Nov 2015
- Pregnancy associated plasma protein-A links pregnancy and melanoma progression by promoting cellular migration and invasion
Journal: Oncotarget
Date: Jun 2015
- Embryonic chicken transplantation is a promising model for studying the invasive behavior of melanoma cells
Journal: Cellular and Phenotypic Plasticity in Cancer
Date: Feb 2015
- Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanoma
Journal: Oncotarget
Date: Jul 2014
- Thrombospondin 1 promotes anin vitroandin vivoinvasive phenotype through epithelial-to-mesenchymal transition in human melanoma
Journal: Pigment Cell & Melanoma Research
Date: July 2014
- Effect of pregnant sera and a pregnancy-associated metalloproteinase (PAPP-A) on melanoma in vitro and in vivo: Insights into melanoma progression during pregnancy and potential new therapeutic targets.
Journal: Journal of Clinical Oncology
Date: July 2014
- Stage I seminoma–treatment choices and outcomes at a single tertiary referral institution
Journal: Bju International
Date:
- Patterns of use of adjuvant therapy in patients with stage 1 NSGCT
Journal: Bju International
Date: July 2013
- Determinants of Resistance to VEGF-TKI and Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma
Journal: Journal of Experimental & Clinical Cancer Research
Date: April 2021
Dr Jason Kelly
B AppSc Bio Med Sc (Hons)
Post Doctoral Researcher
Publications
- Knock down of TIMP-2 by siRNA and CRISPR/Cas9 mediates diverse cellular reprogramming of metastasis and chemosensitivity in ovarian cancer
Journal: Cancer Cell International
Date: Feb 2023
Dr Farah Ahmady
BBioMedSc (Hons) PhD
Post Doctoral Researcher
Dr Arpita Poddar
PhD
Post Doctoral Research Fellow
Dr Arpita Poddar graduated with her PhD in 2021 at RMIT University and the Commonwealth Scientific and Industrial Research Organisation (CSIRO), Melbourne, where she worked on the application of nanoparticles in cancer treatment. An interdisciplinary researcher – her interests are at the interface of materials science, biology and cancer research. Working in collaboration with NHMRC clinical trials centre in the University of Sydney, Graz University of Technology, Austria, the ALBA Synchrotron, Barcelona and the Elettra Sincrotrone, Italy, she developed non-viral alternatives using nanotech to target prostate cancer cells for gene therapy. She has been a recipient of several prestigious Scholarships/bursaries including CSIR-UGC National Eligibility (Govt of India), CSIRO-RMIT research and RMIT-HDR talent award (PhD program), Top Downloaded Paper 2018-2019 and the Australian Nanotechnology Network travel award (twice) to visit and work in Europe. Dr Poddar has since worked in the Walter and Eliza Hall Institute of Medical Research, Melbourne, on understanding the structural biology of genes involved in Alzheimer’s Disease. She has held research fellowship at Monash University where she studied nanomaterials and their interaction with biomolecules. Dr Poddar has established novel nanomaterials as viable, physiologically stable and facile non-viral gene therapy systems, and she is currently applying the delivery systems across different cancer streams with a particular focus on triple negative breast cancer.
Publications
- Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer
Journal: Current Oncology
Date: Oct 2022
Dr Ruth Escalona
PhD
Post Doctoral Research Fellow
Publications
- In Vitro and In Silico Analysis of Epithelial-Mesenchymal Transition and Cancer Stemness as Prognostic Markers of Clear Cell Renal Cell Carcinoma
Journal: Cancers
Date: May 2023
- Knock down of TIMP-2 by siRNA and CRISPR/Cas9 mediates diverse cellular reprogramming of metastasis and chemosensitivity in ovarian cancer
Journal: Cancer Cell International
Date: Feb 2023
Brendan Toohey
BSc
Researcher
Brendan joined the Institute after working in Melbourne research facilities. In his early research career, he worked at the Austin Research Institute, where he was involved in early human clinical trials of antibody immunoconjugates for the treatment of colon and breast cancers. He then moved on to work with Professor Simon Foote at the Walter and Eliza Hall Institute of Medical Research, successfully demonstrating ‘proof of concept’ for a novel mass spectroscopy based method for the detection of single nucleotide polymorphisms (SNP’s). Brendan next became involved in a biotechnology start-up, helping to develop and commercialise a new method for detecting high risk strains of the human papilloma virus using flow cytometry. At the Institute, he has been involved in lung cancer chemotherapy sensitivity trials and is currently investigating a suspected new mechanism of immune cell inhibition caused by cancer cells.
Megan Earls
BBiomedSc (Hons)
Tissue Coordinator
Megan completed honours in Biomedical Science at the Institute in 2014. She joined the staff in 2015 as the Tissue Bank Coordinator, and her main role is to isolate immune cells from blood, tumour and bone marrow.
Professor Stuart Berzins
BSc (Hons) PhD GCUT
Visiting Research Fellow
Publications
- Thymic development of unconventional T cells: how NKT cells, MAIT cells and γδ T cells emerge
Journal: Nature Reviews Immunology
Date: June 2020
- High CD26 and Low CD94 Expression Identifies an IL-23 Responsive Vδ2+ T Cell Subset with a MAIT Cell-like Transcriptional Profile
Journal: Cell Reports
Date: June 2020
- A Role for MAIT Cells in Colorectal Cancer
Journal: Frontiers in Immunology
Date: May 2020
- Foxp3+ Tregs from Langerhans cell histiocytosis lesions co-express CD56 and have a definitively regulatory capacity
Journal: Clinical Immunology
Date: April 20
- Chronically stimulated human MAIT cells are unexpectedly potent IL-13 producers
Journal: Immunology & Cell Biology 2019
Date: July 2019
- Altered Populations of Unconventional T Cell Lineages in Patients with Langerhans Cell Histiocytosis
Journal: Scientific Reports
Date: 2018
- Temporal Regulation of Natural Killer T Cell Interferon Gamma Responses by β-Catenin-Dependent and Independent Wnt Signaling.
Journal: Frontiers in Immunology Volume 9- Article 483
Date: March 2018
- A potentially important role for T cells and regulatory T cells in Langerhans cell histiocytosis
Journal: Clinical Immunology and Immunopathology
Date: 2018
- Human blood MAIT cell subsets defined using MR1 tetramers.
Journal: Immunology and Cell Biology
Date: March 2018
- Experimental and Human Evidence for Lipocalin-2 (Neutrophil Gelatinase-Associated Lipocalin [NGAL]) in the Development of Cardiac Hypertrophy and heart failure.
Journal: Journal American Heart Assoc.
Date: June 2017
- A three-stage intrathymic development pathway for the mucosal-associated invariant T cell lineage
Journal: Nat Immunol
Date: September 2016
- An emerging role for immune regulatory subsets in chronic lymphocytic leukaemia.
Journal: International Immunopharmacol
Date: Apr 2015
- Natural killer T cells: drivers or passengers in preventing human disease?
Journal: National Review of Immunology
Date: Sep 2014
- The glucocorticoid receptor 1A3 promoter correlates with high sensitivity to glucocorticoid-induced apoptosis in human lymphocytes.
Journal: Immunol Cell Biol
Date: Jul 2014
- Acute exercise leads to regulation of telomere-associated genes and microRNA expression in immune cells.
Journal: PLoS One
Date: Apr 2014
- Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy.
Journal: Clin Exp Immunol
Date: Jan 2014
- Ex-vivo analysis of human natural killer T cells demonstrates heterogeneity between tissues and within established CD4(+) and CD4(-) subsets.
Journal: Clin Exp Immunol
Date: Apr 2013
- The BH3-only proteins Bim and Puma cooperate to impose deletional tolerance of organ-specific antigens
Journal: Immunity
Date: Sep 2012
- The NF-κB1 transcription factor prevents the intrathymic development of CD8 T cells with memory properties.
Journal: EMBO J
Date: Nov 11
- Presumed guilty: natural killer T cell defects and human disease.
Journal: Nt Rev Immunol
Date: Feb 2011
- Lessons learned from an unusual presentation of CD3+, CD56- T-cell large granular lymphocyte leukemia.
Journal: Journal of Clinical Oncologoy
Date: Oct 2010
- Transcriptional regulation of lymphocyte development. Developing NKT cells need their (E) protein.
Journal: Immunol Cell Biology
Date: May 2010
- Divergent SATB1 expression across human life-span and tissue compartments
Journal: Immunology & Cell Biology
Date: 2019
- Testing the NKT cell hypothesis in lenalidomide-treated myelodysplastic syndrome patients.
Journal: Leukemia
Date: Jan 2010
- An NZW-derived interval on chromosome 7 moderates sialadenitis, but not insulitis in congenic nonobese diabetic mice.
Journal: Journal of Immunology
Date: Jan 2010
- Immune characterization of an individual with an exceptionally high natural killer T cell frequency and her immediate family.
Journal: Clin Exp Immunol
Date: May 2009
- NKT cell development in the absence of the autoimmune regulator gene (Aire).
Journal: European Journal of Immunology
Date: Sep 2008
- Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population.
Journal: Proc Natl Acad Sci U S A
Date: Aug 2008
- Peripheral NK1.1 NKT cells are mature and functionally distinct from their thymic counterparts.
Journal: Journal of Immunol
Date: Nov 2007
- Control points in NKT-cell development.
Journal: Nat Review Immunol
Date: Aug 2007
- Retraction: Antigen-induced tolerance by intrathymic modulation of self-recognizing inhibitory receptors.
Journal:
Date: 2007
- Antigen challenge inhibits thymic emigration.
Journal: J Immunol
Date: Apr 2006
- Long-term retention of mature NK1.1+ NKT cells in the thymus.
Journal: J Immunol
Date: Apr 2006
- Localization of Idd11 is not associated with thymus and nkt cell abnormalities in NOD mice.
Journal: Diabetes
Date: Dec 2005
- Differential antitumor immunity mediated by NKT cell subsets in vivo.
Journal: J Exp Med
Date: Nov 2005
- The influence of CD1d in postselection NKT cell maturation and homeostasis.
Journal: J Immunol
Date: Sep 2005
- The cellular mechanism of Aire control of T cell tolerance.
Journal: Immunity
Date: Aug 2005
- Activation of thymic regeneration in mice and humans following androgen blockade.
Journal: Journal of Immunology
Date: Aug 2005
- Working with NKT cells--pitfalls and practicalities.
Journal: Curr Opin Immunol
Date: Jun 2005
- Limited correlation between human thymus and blood NKT cell content revealed by an ontogeny study of paired tissue samples.
Journal: European Journal Immunology
Date: Apr 2005
- Are we really on the right TRAIL?
Journal: Immunol Res
Date: Jun 2005
- Parallels and distinctions between T and NKT cell development in the thymus.
Journal: Immunol Cell Biol
Date: Jun 2004
- Systemic NKT cell deficiency in NOD mice is not detected in peripheral blood: implications for human studies.
Journal: Immunol Cell Biology
Date: Jun 2004
- Antigen-induced tolerance by intrathymic modulation of self-recognizing inhibitory receptors
Journal: RETRACTION
Date: 2004
- Normal thymocyte negative selection in TRAIL-deficient mice.
Journal: Journal Exp Med
Date: Aug 2003
- T-cell compartments of prediabetic NOD mice.
Journal: Diabetes
Date: Feb 2003
- Thymic regeneration: teaching an old immune system new tricks.
Journal: Trends Mol Med
Date: Oct 2002
- Projection of an immunological self shadow within the thymus by the aire protein.
Journal: Science
Date: Oct 2002
- Essential role for the lymphostromal plasma membrane Ly-6 superfamily molecule thymic shared antigen 1 in development of the embryonic adrenal gland.
Journal: Mol Cell Biol
Date: Nov 2002
- A central role for thymic emigrants in peripheral T cell homeostasis.
Journal: Proc Natl Acad Sci U S A
Date: Aug 1999
- Thymic shared antigen-2: a novel cell surface marker associated with T cell differentiation and activation.
Journal: Journal Immunol
Date: May 1999
- The role of the thymus and recent thymic migrants in the maintenance of the adult peripheral lymphocyte pool.
Journal: J Exp Med
Date: Jun 1998
- Expression of the gastric H/K-ATPase alpha-subunit in the thymus may explain the dominant role of the beta-subunit in the pathogenesis of autoimmune gastritis.
Journal: Autoimmunity
Date: Jun 2005
Dr Morgan Wallace
BSc (Hons) PhD
Visiting Research Fellow
Morgan Wallace is a lecturer in Biomedical science at Federation University and an Honoarary Research Fellow at the Fiona Elsey Cancer Research Institute. Morgan has worked as a research scientist at several leading research institutes including the University of Massachusetts (USA) the Peter MacCallum Cancer Centre and St Vincent’s Institute in Melbourne. She is currently working with researchers at the Institute to investigate the role of the immune system in fighting haematological cancers including Chronic Lymphocytic Leukaemia and Multiple Myeloma.
Dr Jenny West
BSc (Hons) PhD
Visiting Research Fellow
Jenny has a background in cell biology and biochemistry and joined the Institute in 2001 before retiring in 2017. She retains a connecting with the research team as a Visiting Research Fellow in supporting and mentoring researchers in their projects.
Dr Emma Gannan
BBioMedSci(Hons) MBBS(Hons) DipAnat MS(BreastSurg) FRACS BreastSurgANZ
Collaborating Clinician- Ballarat
Dr Emma Gannan is a specialist breast surgeon. Emma has a particular interest in oncoplastic breast surgery and manages all surgical aspects of benign and malignant breast disease. Emma performs the full range of oncoplastic breast surgery, including implant reconstruction. Emma practices multi-disciplinary breast cancer care and has an interest in medical research. Emma also enjoys her role as a lecturer teaching medical students.